2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentDysregulation of the Scribble/YAP/β‐catenin axis sustains the fibroinflammatory response in a PKHD1−/− mouse model of congenital hepatic fibrosis
Fabris L, Milani C, Fiorotto R, Mariotti V, Kaffe E, Seller B, Sonzogni A, Strazzabosco M, Cadamuro M. Dysregulation of the Scribble/YAP/β‐catenin axis sustains the fibroinflammatory response in a PKHD1−/− mouse model of congenital hepatic fibrosis. The FASEB Journal 2022, 36: e22364. PMID: 35593740, PMCID: PMC9150862, DOI: 10.1096/fj.202101924r.Peer-Reviewed Original ResearchConceptsYes-associated proteinPlanar cell polarityΒ-cateninΒ-catenin axisYAP nuclear importRole of ScribbleNuclear translocationYAP/TAZΒ-catenin signalingCell polarityNuclear importCyst cellsNuclear expressionScribble expressionΒ-catenin nuclear expressionConditional deletionGenetic defectsTissue growth factor expressionIntegrin β6Connective tissue growth factor expressionCyst growthExpressionCystic cholangiocytesMRNA levelsScribbles
2021
The Neglected Role of Bile Duct Epithelial Cells in NASH
Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars In Liver Disease 2021, 42: 034-047. PMID: 34794182, DOI: 10.1055/s-0041-1739455.Peer-Reviewed Original ResearchMeSH KeywordsBile DuctsEpithelial CellsHumansInflammationInsulin ResistanceLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseaseConceptsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisLiver diseaseInsulin resistancePrevalent liver diseaseBile duct epithelial cellsFatty liver diseaseSubset of patientsCommon pathogenetic mechanismDuct epithelial cellsMultiple biological effectsFibro-inflammationHepatic manifestationNAFLD patientsPortal fibrosisMetabolic syndromeBile ductDuctular reactionDisease progressionPathogenetic mechanismsLiver cancerMetabolic alterationsProgenitor cell compartmentEpithelial cellsDisease
2019
Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology
Strazzabosco M, Cortesi P, Conti S, Okolicsanyi S, Rota M, Ciaccio A, Cozzolino P, Fornari C, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Zavaglia C, Perricone G, Munari L, Mantovani L, Belli L. Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology. Liver International 2019, 40: 60-73. PMID: 31654608, PMCID: PMC10916792, DOI: 10.1111/liv.14285.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCarcinoma, HepatocellularFemaleGastroenterologyHepatitis B, ChronicHepatitis C, ChronicHumansItalyLiver CirrhosisLiver NeoplasmsLongitudinal StudiesMaleMiddle AgedProspective StudiesQuality Indicators, Health CareSurvival AnalysisTreatment OutcomeValue-Based Health InsuranceConceptsClinical outcome indicatorsClinical practiceOutcome indicatorsChronic hepatitis BClinical practice settingMajor health problemCurrent international guidelinesNew effective treatmentsValue of careMETHODS/RESULTSHCV patientsHCV infectionHepatitis BClinical outcomesLiver diseaseMulticentre studyEffective treatmentHealth problemsInternational guidelinesCare deliveryValue-based medicineCostly treatmentPractice settingsHBVPatients
2018
Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies
Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M. Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. International Journal Of Molecular Sciences 2018, 19: 3875. PMID: 30518128, PMCID: PMC6321547, DOI: 10.3390/ijms19123875.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Duct DiseasesEpitheliumHumansLiverLiver CirrhosisMesodermPrecancerous ConditionsConceptsMain molecular mechanismsDifferent lineagesPrimary sclerosing cholangitisMolecular mechanismsProfibrotic chemokinesNeoplastic transformationSclerosing cholangitisCaroli's diseaseOrgan dysfunctionChronic cholangiopathiesInflammatory infiltrateLiver injuryPeriportal fibrosisLiver diseaseInflammatory cellsProinflammatory cytokinesBiliary treePreneoplastic conditionsDifferent etiologiesTumor developmentMurine modelLiver responseParacrine fashionHepatic responseCellular typesForecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego A, Brunetto M, Raimondo G, Taliani G, Iannone A, Russo F, Santantonio T, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne E, Strazzabosco M, Massari M, Lampertico P, Rumi M, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta M, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A, Group P. Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? Liver International 2018, 38: 2190-2198. PMID: 29900654, PMCID: PMC6282782, DOI: 10.1111/liv.13901.Peer-Reviewed Original ResearchConceptsHCV elimination goalsElimination goalsBirth cohortHCV-endemic countriesLiver disease burdenCare scenariosHigh prevalence groupPublic health initiativesEligible patientsAntiviral treatmentPrevalence groupDisease burdenViraemic infectionsBurden estimatesEndemic countriesPatientsCare individualsHealth initiativesAbstractTextTreatment ratesCohortScreening strategyEligible poolTreatmentPotential strategyImpact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C, Association A. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal Of Hepatology 2018, 69: 810-817. PMID: 29940268, DOI: 10.1016/j.jhep.2018.06.010.Peer-Reviewed Original ResearchConceptsHepatitis C virusNon-alcoholic steatohepatitisHepatitis B virusEuropean Liver Transplant RegistryLiver transplantationSurvival of recipientsDAA eraLiver diseaseHepatocellular carcinomaEvolution of indicationsVirus infectionNumber of LTsHepatitis B virus infectionHepatitis C virus infectionAdult liver transplantationAdvent of DAAsImpact of DAAsLiver Transplant RegistrySecond-generation DAAsC virus infectionLiver transplant recipientsOutcomes of patientsB virus infectionThree-year survivalDAA treatmentβ‐Catenin and interleukin‐1β–dependent chemokine (C‐X‐C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis
Kaffe E, Fiorotto R, Pellegrino F, Mariotti V, Amenduni M, Cadamuro M, Fabris L, Strazzabosco M, Spirli C. β‐Catenin and interleukin‐1β–dependent chemokine (C‐X‐C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis. Hepatology 2018, 67: 1903-1919. PMID: 29140564, PMCID: PMC5906178, DOI: 10.1002/hep.29652.Peer-Reviewed Original ResearchConceptsSignal transducerΒ-cateninJanus kinase/signal transducerKinase/signal transducerActivator of transcriptionProtein kinase ATranscription 3 (STAT3) phosphorylationHepatic disease 1 (PKHD1) geneNOD-like receptorsKinase ATranscription 3Novel therapeutic avenuesGenetic diseasesNuclear translocationCognate receptorsFamily 3Nuclear factorMouse modelPKHD1Activated B cellsPhosphorylationActivatorCyst growthTherapeutic avenuesAMG 487The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2017
Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75
2016
Macrophage recruitment by fibrocystin‐defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis
Locatelli L, Cadamuro M, Spirlì C, Fiorotto R, Lecchi S, Morell C, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M. Macrophage recruitment by fibrocystin‐defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 2016, 63: 965-982. PMID: 26645994, PMCID: PMC4764460, DOI: 10.1002/hep.28382.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, NeoplasmChemokinesClodronic AcidCollagenDisease Models, AnimalEpithelial CellsGenetic Diseases, InbornIntegrinsLiver CirrhosisMacrophagesMiceMyofibroblastsReceptors, Cell SurfaceSnail Family Transcription FactorsTranscription FactorsTransforming Growth Factor beta1Tumor Necrosis Factor-alphaConceptsCongenital hepatic fibrosisMacrophage recruitmentPortal hypertensionPortal fibrosisHepatic fibrosisLiver fibrosisCell dysfunctionBile duct changesRange of chemokinesLow-grade inflammationProgressive liver fibrosisDuctal plate malformationEpithelial cell dysfunctionGrowth factor-β1Biliary epithelial cellsBiliary fibrosisLiver failureMacrophage infiltratesLiver cystsDuct changesProinflammatory cytokinesPeribiliary fibrosisBiliary epitheliumDisease progressionM1 phenotype
2014
Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury
Strazzabosco M, Fabris L, Albano E. Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. Gut 2014, 63: 1693. PMID: 25056656, PMCID: PMC4519840, DOI: 10.1136/gutjnl-2014-307712.Peer-Reviewed Original Research
2013
Protein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis
Spirli C, Locatelli L, Morell CM, Fiorotto R, Morton SD, Cadamuro M, Fabris L, Strazzabosco M. Protein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology 2013, 58: 1713-1723. PMID: 23744610, PMCID: PMC3800498, DOI: 10.1002/hep.26554.Peer-Reviewed Original ResearchConceptsAutosomal recessive polycystic kidney diseaseCongenital hepatic fibrosisCaroli's diseaseΒ-cateninHepatic fibrosisRac-1 inhibitionIntrahepatic bile ductsRecessive polycystic kidney diseasePotential therapeutic targetPolycystic kidney diseaseStimulation of cAMPRac-1 activityE-cadherin expressionBile ductKidney diseaseLiver pathologyCystic dysplasiaMouse modelTherapeutic targetTranscriptional activityNuclear translocationDiseasePKA blockerCholangiocytesFibrosis
2010
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C
Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M, Pierantonelli I, Trozzi L, Bugianesi E, Guido M, Strazzabosco M, Benedetti A, Marchesini G. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 2010, 60: 108. PMID: 20966027, PMCID: PMC3784835, DOI: 10.1136/gut.2010.219741.Peer-Reviewed Original ResearchConceptsChronic hepatitis CFibroblast-specific protein-1Epithelial-mesenchymal transitionInsulin resistanceDuctular reactionHepatitis CHepatic fibrosisEpithelial componentOral glucose insulin sensitivityOral glucose tolerance testTertiary care academic centerEpithelial-mesenchymal transition (EMT) markersNuclear Snail expressionProspective observational studyGlucose insulin sensitivityGlucose tolerance testDegree of necroinflammationStage of fibrosisTissue repairCK7-positive cellsNecroinflammatory activityNecroinflammatory scoreAdvanced fibrosisConsecutive patientsTotal inflammationCholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease
Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M, Stroffolini T, committee F. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “Cholangiocarcinoma” committee of the Italian Association for the Study of Liver disease. Digestive And Liver Disease 2010, 43: 60-65. PMID: 20580332, DOI: 10.1016/j.dld.2010.05.002.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAgedBile Duct NeoplasmsBile Ducts, ExtrahepaticBile Ducts, IntrahepaticCholangiocarcinomaCholangiopancreatography, Endoscopic RetrogradeCholangiopancreatography, Magnetic ResonanceData CollectionDiarrheaFatigueFemaleHepatitis CHumansItalyJaundiceLiver CirrhosisMaleMiddle AgedNauseaTomography, X-Ray ComputedUltrasonographyVomitingWeight LossConceptsClinical characteristicsIH-CCAAsymptomatic presentationEH-CCACoexistence of cirrhosisCurative surgical treatmentTissue-proven diagnosisNational surveyCurative intentSurgical treatmentViral cirrhosisLiver diseaseOpen surgeryDiagnostic managementDiagnostic modalitiesCholangiocarcinoma casesCholangiocarcinomaYounger ageItalian AssociationCirrhosisDifferent imaging proceduresImaging proceduresDiagnosisTreatmentAgeGenetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C
Hov JR, Lleo A, Selmi C, Woldseth B, Fabris L, Strazzabosco M, Karlsen TH, Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. Journal Of Hepatology 2010, 52: 712-717. PMID: 20347497, DOI: 10.1016/j.jhep.2009.11.029.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCholangitis, SclerosingChromosome MappingChromosomes, Human, Pair 6EuropeFemaleGene FrequencyHLA-B AntigensHLA-C AntigensHLA-DR AntigensHLA-DRB1 ChainsHumansInflammatory Bowel DiseasesItalyLiver CirrhosisMaleMicrosatellite RepeatsMiddle AgedReference ValuesRisk AssessmentYoung AdultConceptsPrimary sclerosing cholangitisSclerosing cholangitisHLA-DRB1Risk of PSCTNF-alpha -308GNatural killer cellsP-valueChi-square testHLA-C2PSC patientsKiller cellsTumor necrosisPSC pathogenesisT lymphocytesSignificant associationAbstractTextMICA locusHLA complexHLADRB1CholangitisUncorrected p-valueKIRFurther studiesAIMS
2008
Prognostic Prediction in Hepatocellular Carcinoma
Strazzabosco M, Cohen E, Emre S. Prognostic Prediction in Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2008, 42: 221-223. PMID: 18223506, DOI: 10.1097/mcg.0b013e31815ed0a9.Peer-Reviewed Original Research
1999
The monoethylglycinexylidide test for grading of liver cirrhosis
FABRIS, JEMMOLO, TOFFOLO, PALEARI, VIAGGI, RIGON, CASAGRANDE, LIRUSSI, STRAZZABOSCO, COBELLI, OKOLICSANYI. The monoethylglycinexylidide test for grading of liver cirrhosis. Alimentary Pharmacology & Therapeutics 1999, 13: 67-75. PMID: 9892881, DOI: 10.1046/j.1365-2036.1999.00431.x.Peer-Reviewed Original ResearchConceptsLiver function testsCirrhotic patientsLignocaine injectionLiver cirrhosisFunction testsMEGX testMEGX concentrationsDynamic liver function testsQuantitative liver function testsCompensated liver cirrhosisGood diagnostic accuracyMonoethylglycinexylidide formationMonoethylglycinexylidide testMEGX formationSerum concentrationsPatientsDisease severityMin-1Diagnostic accuracyCirrhosisOptimal sampling timesGood discriminationInjectionNormals
1985
Pharmacokinetics of Josamycin in patients with liver cirrhosis and Gilbert's syndrome after repeated doses.
Okolicsanyi L, Venuti M, Strazzabosco M, Biral A, Orlando R, Iemmolo R, Nassuato G, Muraca M, Padrini G, Miglioli P. Pharmacokinetics of Josamycin in patients with liver cirrhosis and Gilbert's syndrome after repeated doses. International Journal Of Clinical Pharmacology And Therapeutics 1985, 23: 434-8. PMID: 4044077.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleGilbert DiseaseHumansHyperbilirubinemia, HereditaryKineticsLeucomycinsLiver CirrhosisMaleMiddle AgedTime Factors
1984
Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
Okolicsanyi L, Venuti M, Strazzabosco M, Orlando R, Nassuato G, Iemmolo R, Lirussi F, Muraca M, Pastorino A, Castelli G. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis. International Journal Of Clinical Pharmacology And Therapeutics 1984, 22: 329-32. PMID: 6086536.Peer-Reviewed Original ResearchConceptsCompensated liver cirrhosisLiver cirrhosisPharmacokinetics of ranitidineCirrhotic patientsUrinary recoveryUnchanged drugHealthy controlsPlasma concentrationsIntravenous pharmacokineticsPharmacokinetic dataPatientsCirrhosisOral bioavailabilityRanitidinePharmacokineticsHigh-performance liquid chromatographyPerformance liquid chromatographyCirrhoticsLiquid chromatographyControl